TY - JOUR
T1 - Trends in pharmaceutical targeting of clinical indications
T2 - 1930-2013
AU - Kinch, Michael S.
AU - Merkel, Janie
AU - Umlauf, Sheila
N1 - Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2014/11
Y1 - 2014/11
N2 - An analysis of FDA-approved new molecular entities (NMEs) reveals trends in therapeutic applications. Four groupings (infectious diseases, cardiovascular diseases, autoimmune/inflammatory diseases and cancer) capture more than 60% of NMEs. Infectious diseases are the most targeted indications. Near the turn of the new millennium, the rate of new approvals for infectious diseases decreased. The absolute and relative number of NMEs targeting psychiatric, neurological and pain/itch indications also declined. By contrast, NMEs targeting cancer have risen in the past two decades as have NMEs targeting orphan indications. These results suggest the drug development community has largely been responsive to public health and market needs. However, finite resources might indicate emphasis on some unmet needs could come at the cost of others.
AB - An analysis of FDA-approved new molecular entities (NMEs) reveals trends in therapeutic applications. Four groupings (infectious diseases, cardiovascular diseases, autoimmune/inflammatory diseases and cancer) capture more than 60% of NMEs. Infectious diseases are the most targeted indications. Near the turn of the new millennium, the rate of new approvals for infectious diseases decreased. The absolute and relative number of NMEs targeting psychiatric, neurological and pain/itch indications also declined. By contrast, NMEs targeting cancer have risen in the past two decades as have NMEs targeting orphan indications. These results suggest the drug development community has largely been responsive to public health and market needs. However, finite resources might indicate emphasis on some unmet needs could come at the cost of others.
UR - http://www.scopus.com/inward/record.url?scp=84910654115&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2014.05.021
DO - 10.1016/j.drudis.2014.05.021
M3 - Short survey
C2 - 24881779
AN - SCOPUS:84910654115
SN - 1359-6446
VL - 19
SP - 1682
EP - 1685
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 11
ER -